Inspiring Innovations; State of Alzheirmer's Therapies - Dr. Leen Kawas

This week's podcast has two parts.  Dr. Leen Kawas , Managing General Partner at Propel Biopartners, speaks about how biotech startups can benefit from skilled oversight and capital provided from experts that understand the business/science ecosystem. In the second part we discuss the latest therapies for Alzheimer's Disease, and how trials and regulation can't follow traditional trajectories. Alzheimer's has variation in etiology, patients start treatments after a diagnosis which may be years after the disease is well established, and progression is dependent on many genetic factors. All of these variables make any assessments problematic. At the same time several new antibody-based therapies show promise.